{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:32:37Z","timestamp":1789500757716,"version":"build-2803163510"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07790-2","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:03:44Z","timestamp":1760774624000},"page":"1145-1159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiotoxicity Induced by Targeted Cancer Therapies: Understanding the Risks and Developing Solutions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7851-2379","authenticated-orcid":false,"given":"Anchal","family":"Chhabra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-2012","authenticated-orcid":false,"given":"Veerta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"7790_CR1","doi-asserted-by":"publisher","unstructured":"Hauwanga WN, McBenedict B, Amadi ES, et al. A systematic review of the cardiotoxic effects of targeted therapies in oncology. Cureus. 2024 Aug 6;16(8). https:\/\/doi.org\/10.7759\/cureus.66258","DOI":"10.7759\/cureus.66258"},{"key":"7790_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.08.029","author":"J Mallidi","year":"2024","unstructured":"Mallidi J, Baylis R, Song EJ. Management of cancer therapy related cardiac dysfunction (CTRCD): a case based review. Am J Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.amjcard.2024.08.029.","journal-title":"Am J Cardiol"},{"issue":"5","key":"7790_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.hlc.2023.12.006","volume":"33","author":"T Yan","year":"2024","unstructured":"Yan T, Yu H, Li T, et al. Mechanisms of cardiovascular toxicities induced by cancer therapies and promising biomarkers for their prediction: a scoping review. Heart Lung Circ. 2024;33(5):605\u201338. https:\/\/doi.org\/10.1016\/j.hlc.2023.12.006.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"7790_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccl.2024.08.002","volume":"43","author":"E Balough","year":"2025","unstructured":"Balough E, Ariza A, Asnani A, et al. Cardiotoxicity of anthracyclines. Cardiol Clin. 2025;43(1):111\u201327. https:\/\/doi.org\/10.1016\/j.ccl.2024.08.002.","journal-title":"Cardiol Clin"},{"key":"7790_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2023.100493","volume":"40","author":"V Sharma","year":"2023","unstructured":"Sharma V, Chhabra T, Singh TG. Correlation of COVID-19 and Guillain-Barr\u00e9 syndrome: a mechanistic perspective. Obes Med. 2023;40:100493. https:\/\/doi.org\/10.1016\/j.obmed.2023.100493.","journal-title":"Obes Med"},{"key":"7790_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-024-07665-y","volume":"14","author":"J Huang","year":"2025","unstructured":"Huang J, Hou X, Zhou N, et al. Novel protective role for gut microbiota-derived metabolite PAGln in doxorubicin-induced cardiotoxicity. Cardiovasc Drugs Ther. 2025;14:1\u20136. https:\/\/doi.org\/10.1007\/s10557-024-07665-y.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7790_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12265-023-10431-4","volume":"17","author":"M Suleiman","year":"2024","unstructured":"Suleiman M, Al Najjar A, Zakaria ZZ, et al. The role of p90 ribosomal S6 kinase (RSK) in tyrosine kinase inhibitor (TKI)-induced cardiotoxicity. J Cardiovasc Transl Res. 2024;17(2):334\u201344. https:\/\/doi.org\/10.1007\/s12265-023-10431-4.","journal-title":"J Cardiovasc Transl Res"},{"key":"7790_CR8","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S469331","author":"F Gao","year":"2024","unstructured":"Gao F, Xu T, Zang F, et al. Cardiotoxicity of anticancer drugs: molecular mechanisms, clinical management and innovative treatment. Drug Des Devel Ther. 2024. https:\/\/doi.org\/10.2147\/DDDT.S469331.","journal-title":"Drug Des Devel Ther"},{"key":"7790_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404692","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Lin Y, Lin S, et al. Advancements in understanding cardiotoxicity of EGFR-TKIs in non-small cell lung cancer treatment and beyond. Front Pharmacol. 2024;15:1404692. https:\/\/doi.org\/10.3389\/fphar.2024.1404692.","journal-title":"Front Pharmacol"},{"key":"7790_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.004","author":"X Lin","year":"2024","unstructured":"Lin X, Ma X, Zhao S, et al. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Trends Cancer. 2024. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.004.","journal-title":"Trends Cancer"},{"issue":"9","key":"7790_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132747","volume":"5","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020;5(9):e132747. https:\/\/doi.org\/10.1172\/jci.insight.132747.","journal-title":"JCI Insight"},{"key":"7790_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-025-07673-6","volume":"26","author":"Y Sun","year":"2025","unstructured":"Sun Y, Xiao L, Chen L, et al. Doxorubicin-induced cardiac remodeling: mechanisms and mitigation strategies. Cardiovasc Drugs Ther. 2025;26:1\u201329. https:\/\/doi.org\/10.1007\/s10557-025-07673-6.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7790_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","volume":"18","author":"CY Kong","year":"2022","unstructured":"Kong CY, Guo Z, Song P, et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int J Biol Sci. 2022;18(2):760. https:\/\/doi.org\/10.7150\/ijbs.65258.","journal-title":"Int J Biol Sci"},{"key":"7790_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-024-07574-0","volume":"16","author":"A Nagy","year":"2024","unstructured":"Nagy A, B\u00f6rzsei D, Hoffmann A, et al. A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms. Cardiovasc Drugs Ther. 2024;16:1\u20135. https:\/\/doi.org\/10.1007\/s10557-024-07574-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"7790_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","volume":"74","author":"IC Jones","year":"2022","unstructured":"Jones IC, Dass CR. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. J Pharm Pharmacol. 2022;74(12):1677\u201388. https:\/\/doi.org\/10.1093\/jpp\/rgac063.","journal-title":"J Pharm Pharmacol"},{"issue":"15","key":"7790_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1089\/ars.2020.8016","volume":"32","author":"C Rocca","year":"2020","unstructured":"Rocca C, Pasqua T, Cerra MC, et al. Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation. Antioxid Redox Signal. 2020;32(15):1081\u201397. https:\/\/doi.org\/10.1089\/ars.2020.8016.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"7790_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-025-01587-w","volume":"40","author":"V Sharma","year":"2025","unstructured":"Sharma V, Sharma P, Singh TG. Ferroptosis and Alzheimer\u2019s: unveiling new avenues for the treatment and prevention. Metab Brain Dis. 2025;40(4):1\u20133. https:\/\/doi.org\/10.1007\/s11011-025-01587-w.","journal-title":"Metab Brain Dis"},{"issue":"3","key":"7790_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031912","volume":"23","author":"BB Wu","year":"2022","unstructured":"Wu BB, Leung KT, Poon EN. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022;23(3):1912. https:\/\/doi.org\/10.3390\/ijms23031912.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"7790_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/ijbs.103810","volume":"21","author":"W Li","year":"2025","unstructured":"Li W, Zhang Y, Wei Y, et al. New insights into mitochondrial quality control in anthracycline-induced cardiotoxicity: molecular mechanisms, therapeutic targets, and natural products. Int J Biol Sci. 2025;21(2):507. https:\/\/doi.org\/10.7150\/ijbs.103810.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"7790_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2353\/ajpath.2008.080019","volume":"173","author":"P Pacher","year":"2008","unstructured":"Pacher P, Szabo C. Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in human disease. Am J Pathol. 2008;173(1):2\u201313.","journal-title":"Am J Pathol"},{"key":"7790_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106849","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy EA, Saber S, Hamad RS, et al. Mechanistic insights into carvedilol\u2019s potential protection against doxorubicin-induced cardiotoxicity. Eur J Pharm Sci. 2024. https:\/\/doi.org\/10.1016\/j.ejps.2024.106849.","journal-title":"Eur J Pharm Sci"},{"key":"7790_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cstres.2024.03.003","author":"T Wang","year":"2024","unstructured":"Wang T, Xing G, Fu T, et al. Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies. Cell Stress Chaperones. 2024. https:\/\/doi.org\/10.1016\/j.cstres.2024.03.003.","journal-title":"Cell Stress Chaperones"},{"issue":"4","key":"7790_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. https:\/\/doi.org\/10.1038\/s41419-021-03614-x.","journal-title":"Cell Death Dis"},{"issue":"10","key":"7790_CR24","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/ATVBAHA.124.319864","volume":"44","author":"RJ Travers","year":"2024","unstructured":"Travers RJ, Stepanian A, Jaffe IZ. Endothelium as a source of cardiovascular toxicity from antitumor kinase inhibitors. Arterioscler Thromb Vasc Biol. 2024;44(10):2143\u201353. https:\/\/doi.org\/10.1161\/ATVBAHA.124.319864.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"7790_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10381-x","volume":"52","author":"R Verma","year":"2025","unstructured":"Verma R, Sharma P, Sharma V, Singh TG. Modulating lipid droplet dynamics in neurodegeneration: an emerging area of molecular pharmacology. Mol Biol Rep. 2025;52(1):277. https:\/\/doi.org\/10.1007\/s11033-025-10381-x.","journal-title":"Mol Biol Rep"},{"key":"7790_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107165","volume":"203","author":"P K\u00fcc\u00fck","year":"2024","unstructured":"K\u00fcc\u00fck P, Abbey L, Schmitt J, et al. Cardiomyocytes, cardiac endothelial cells and fibroblasts contribute to anthracycline-induced cardiac injury through RAS-homologous small GTPases RAC1 and CDC42. Pharmacol Res. 2024;203:107165. https:\/\/doi.org\/10.1016\/j.phrs.2024.107165.","journal-title":"Pharmacol Res"},{"issue":"306","key":"7790_CR27","doi-asserted-by":"publisher","first-page":"135562","DOI":"10.1016\/j.chemosphere.2022.135562","volume":"1","author":"J Wang","year":"2022","unstructured":"Wang J, Gao X, Liu F, et al. Difenoconazole causes cardiotoxicity in common carp (Cyprinus carpio): involvement of oxidative stress, inflammation, apoptosis and autophagy. Chemosphere. 2022;1(306):135562. https:\/\/doi.org\/10.1016\/j.chemosphere.2022.135562.","journal-title":"Chemosphere"},{"issue":"3","key":"7790_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","volume":"3","author":"S Tousif","year":"2023","unstructured":"Tousif S, Singh AP, Umbarkar P, et al. Ponatinib drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1\u03b2 mediated inflammation. Circ Res. 2023;3(3):267\u201389. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321504.","journal-title":"Circ Res"},{"key":"7790_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-024-02131-5","volume":"8","author":"E Hutchins","year":"2024","unstructured":"Hutchins E, Yang EH, Stein-Merlob AF. Inflammation in chemotherapy-induced cardiotoxicity. Curr Cardiol Rep. 2024;8:1\u20132. https:\/\/doi.org\/10.1007\/s11886-024-02131-5.","journal-title":"Curr Cardiol Rep"},{"key":"7790_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105266","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266.","journal-title":"EBioMedicine"},{"issue":"7","key":"7790_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024;15(7):903. https:\/\/doi.org\/10.3390\/genes15070903.","journal-title":"Genes"},{"issue":"18","key":"7790_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810046","volume":"25","author":"L Liu","year":"2024","unstructured":"Liu L, Soler J, Reckamp KL, et al. Emerging targets in non-small cell lung cancer. Int J Mol Sci. 2024;25(18):10046. https:\/\/doi.org\/10.3390\/ijms251810046.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"7790_CR33","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","volume":"38","author":"J Korbecki","year":"2024","unstructured":"Korbecki J, Bosiacki M, Kupnicka P, et al. CXCR4 as a therapeutic target in acute myeloid leukemia. Leukemia. 2024;38(11):2303\u201317. https:\/\/doi.org\/10.1038\/s41375-024-02326-3.","journal-title":"Leukemia"},{"issue":"5","key":"7790_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-024-01431-x","volume":"24","author":"FE Meinag","year":"2024","unstructured":"Meinag FE, Fatahi M, Vahedian V, et al. Modulatory effects of miRNAs in doxorubicin resistance: a mechanistic view. Funct Integr Genomics. 2024;24(5):150. https:\/\/doi.org\/10.1007\/s10142-024-01431-x.","journal-title":"Funct Integr Genomics"},{"key":"7790_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/bs.vh.2025.01.003","volume":"128","author":"AB Littleflower","year":"2025","unstructured":"Littleflower AB, Parambil ST, Antony GR, et al. Glut-1 inhibition in breast cancer cells. Vitam Horm. 2025;128:181\u2013211. https:\/\/doi.org\/10.1016\/bs.vh.2025.01.003.","journal-title":"Vitam Horm"},{"issue":"8","key":"7790_CR36","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","volume":"67","author":"H Deng","year":"2024","unstructured":"Deng H, Han Y, Liu L, et al. Targeting myeloid leukemia-1 in cancer therapy: advances and directions. J Med Chem. 2024;67(8):5963\u201398. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01998.","journal-title":"J Med Chem"},{"key":"7790_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N, et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188:21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"44","key":"7790_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005195","volume":"1","author":"Z Jawa","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore). 2016;1(44):e5195. https:\/\/doi.org\/10.1097\/MD.0000000000005195.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"7790_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","volume":"16","author":"S Martel","year":"2017","unstructured":"Martel S, Maurer C, Lambertini M, et al. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16(9):1021\u201338. https:\/\/doi.org\/10.1080\/14740338.2017.1351541.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"7790_CR40","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/j.orcp.2013.12.005","volume":"8","author":"IA Ebong","year":"2014","unstructured":"Ebong IA, Goff DC Jr, Rodriguez CJ, et al. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014;8(6):e540\u20138.","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"7790_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10557-023-07457-w","volume":"39","author":"J Li","year":"2025","unstructured":"Li J, Lee AR, Tariq A, et al. Comparing renin-angiotensin-aldosterone blockade regimens for long-term chemotherapy-related cardiac dysfunction: a network meta-analysis. Cardiovasc Drugs Ther. 2025;39(1):171\u201386. https:\/\/doi.org\/10.1007\/s10557-023-07457-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"7790_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5334\/gh.1399","volume":"20","author":"M Rahman","year":"2025","unstructured":"Rahman M, Alatiqi M, Al Jarallah M, Hussain MY, Monayem A, Panduranga P, et al. Cardiovascular effects of smoking and smoking cessation: a 2024 update. Global Heart. 2025;20(1):15. https:\/\/doi.org\/10.5334\/gh.1399.","journal-title":"Global Heart"},{"issue":"3","key":"7790_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","volume":"34","author":"B Messner","year":"2014","unstructured":"Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7790_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07522-4","author":"S Wei","year":"2023","unstructured":"Wei S, Ma W, Xie S, et al. Hyperoside protects trastuzumab-induced cardiotoxicity via activating the PI3K\/Akt signaling pathway. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07522-4.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"7790_CR45","doi-asserted-by":"publisher","first-page":"695792","DOI":"10.3389\/fmed.2021.695792","volume":"30","author":"T Salvatore","year":"2021","unstructured":"Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, et al. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. Front Med. 2021;30(8):695792. https:\/\/doi.org\/10.3389\/fmed.2021.695792.","journal-title":"Front Med"},{"issue":"9","key":"7790_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2v","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nature Rev Cardiol. 2020;17(9):585\u2013607. https:\/\/doi.org\/10.1038\/s41569-020-0339-2v.","journal-title":"Nature Rev Cardiol"},{"issue":"10","key":"7790_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cardfail.2016.03.013","volume":"22","author":"J Yeboah","year":"2016","unstructured":"Yeboah J, Rodriguez CJ, Qureshi W, et al. Prognosis of low normal left ventricular ejection fraction in an asymptomatic population-based adult cohort: the Multiethnic Study of Atherosclerosis. J Card Fail. 2016;22(10):763\u20138.","journal-title":"J Card Fail"},{"issue":"1","key":"7790_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13377-1","volume":"24","author":"F Zhang","year":"2024","unstructured":"Zhang F, Wang S, Yu C, et al. The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy. BMC Cancer. 2024;24(1):1585. https:\/\/doi.org\/10.1186\/s12885-024-13377-1.","journal-title":"BMC Cancer"},{"issue":"3","key":"7790_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10557-024-07555-3","volume":"39","author":"S Liu","year":"2025","unstructured":"Liu S, Liu J, Su N, et al. An integrated network pharmacology and RNA-seq approach for exploring the protective effect of andrographolide in doxorubicin-induced cardiotoxicity. Cardiovasc Drugs Ther. 2025;39(3):517\u201331. https:\/\/doi.org\/10.1007\/s10557-024-07555-3.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7790_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-025-07674-5","volume":"6","author":"MM Hulsurkar","year":"2025","unstructured":"Hulsurkar MM, Wehrens XH. Doxorubicin-induced cardiotoxicity: can andrographolide provide a silver lining? Cardiovasc Drugs Ther. 2025;6:1\u20135. https:\/\/doi.org\/10.1007\/s10557-025-07674-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"18","key":"7790_CR51","doi-asserted-by":"publisher","first-page":"10177","DOI":"10.3390\/ijms251810177","volume":"25","author":"R Jiang","year":"2024","unstructured":"Jiang R, Lou L, Shi W, et al. Statins in mitigating anticancer treatment-related cardiovascular disease. Int J Mol Sci. 2024;25(18):10177. https:\/\/doi.org\/10.3390\/ijms251810177.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"7790_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging10080193","volume":"10","author":"A Moradi","year":"2024","unstructured":"Moradi A, Olanisa OO, Nzeako T, et al. Revolutionizing cardiac imaging: a scoping review of artificial intelligence in echocardiography, CTA, and cardiac MRI. J Imaging. 2024;10(8):193. https:\/\/doi.org\/10.3390\/jimaging10080193.","journal-title":"J Imaging"},{"issue":"7","key":"7790_CR53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11886-024-02068-9","volume":"26","author":"JA Pan","year":"2024","unstructured":"Pan JA, Patel AR. The role of multimodality imaging in cardiomyopathy. Curr Cardiol Rep. 2024;26(7):689\u2013703. https:\/\/doi.org\/10.1007\/s11886-024-02068-9.","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"7790_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging10090230","volume":"10","author":"N Baba Ali","year":"2024","unstructured":"Baba Ali N, Attaripour Esfahani S, Scalia IG, et al. The role of cardiovascular imaging in the diagnosis of athlete\u2019s heart: navigating the shades of grey. J Imaging. 2024;10(9):230. https:\/\/doi.org\/10.3390\/jimaging10090230.","journal-title":"J Imaging"},{"key":"7790_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","volume":"3","author":"B Rachma","year":"2025","unstructured":"Rachma B, Savitri M, Sutanto H. Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management. Cancer Pathogen Ther. 2025;3:101\u20138. https:\/\/doi.org\/10.1016\/j.cpt.2024.04.004.","journal-title":"Cancer Pathogen Ther"},{"issue":"5","key":"7790_CR56","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","volume":"2","author":"JE Liu","year":"2020","unstructured":"Liu JE, Barac A, Thavendiranathan P, et al. Strain imaging in cardio-oncology. JACC: CardioOncol. 2020;2(5):677\u201389. https:\/\/doi.org\/10.1016\/j.jaccao.2020.10.011.","journal-title":"JACC: CardioOncol"},{"issue":"6","key":"7790_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15060787","volume":"15","author":"LC Nechita","year":"2025","unstructured":"Nechita LC, Tutunaru D, Nechita A, et al. AI and smart devices in cardio-oncology: advancements in cardiotoxicity prediction and cardiovascular monitoring. Diagnostics. 2025;15(6):787. https:\/\/doi.org\/10.3390\/diagnostics15060787.","journal-title":"Diagnostics"},{"issue":"752","key":"7790_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl5931","volume":"16","author":"Y Pan","year":"2024","unstructured":"Pan Y, Wang C, Zhou W, et al. Inhibiting AGTR1 reduces AML burden and protects the heart from cardiotoxicity in mouse models. Sci Transl Med. 2024;16(752):eadl5931. https:\/\/doi.org\/10.1126\/scitranslmed.adl5931.","journal-title":"Sci Transl Med"},{"key":"7790_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108116","volume":"237","author":"JD Terwoord","year":"2022","unstructured":"Terwoord JD, Beyer AM, Gutterman DD. Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther. 2022;237:108116.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"7790_CR60","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","volume":"30","author":"S Shil","year":"2025","unstructured":"Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025;30(5):1075\u201392.","journal-title":"Heart Fail Rev"},{"key":"7790_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-024-07604-x","volume":"39","author":"CA Gongora","year":"2024","unstructured":"Gongora CA, Zhang L, Mattei JL, et al. Are sodium-glucose cotransporter-2 inhibitors the cherry on top of cardio-oncology care? Cardiovasc Drugs Ther. 2024;39:1\u20138. https:\/\/doi.org\/10.1007\/s10557-024-07604-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7790_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-025-07769-z","volume":"26","author":"J Yan","year":"2025","unstructured":"Yan J, Lin K, Dai S, et al. Class effect of SGLT2 inhibitors against doxorubicin-induced cardiotoxicity via regulating adenosine kinase mediated-cardiac oxidative stress. Cardiovasc Drugs Ther. 2025;26:1\u20135. https:\/\/doi.org\/10.1007\/s10557-025-07769-z.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7790_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae084","author":"J Chen","year":"2024","unstructured":"Chen J, Wei J, Xia P, et al. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy. Cardiovasc Res. 2024. https:\/\/doi.org\/10.1093\/cvr\/cvae084.","journal-title":"Cardiovasc Res"},{"issue":"34","key":"7790_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310227","volume":"11","author":"J Cui","year":"2024","unstructured":"Cui J, Chen Y, Yang Q, et al. Protosappanin a protects DOX-induced myocardial injury and cardiac dysfunction by targeting ACSL4\/FTH1 axis-dependent ferroptosis. Adv Sci. 2024;11(34):2310227. https:\/\/doi.org\/10.1002\/advs.202310227.","journal-title":"Adv Sci"},{"key":"7790_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155473","volume":"127","author":"W Li","year":"2024","unstructured":"Li W, Cao J, Zhang Y, et al. Aucubin alleviates doxorubicin-induced cardiotoxicity through crosstalk between NRF2 and HIPK2 mediating autophagy and apoptosis. Phytomedicine. 2024;127:155473. https:\/\/doi.org\/10.1016\/j.phymed.2024.155473.","journal-title":"Phytomedicine"},{"key":"7790_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae188","author":"X Zhou","year":"2024","unstructured":"Zhou X, Liu Y, Shen Y, et al. Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1\u03b1. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae188.","journal-title":"Eur Heart J"},{"issue":"1","key":"7790_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02301-y","volume":"23","author":"Y Fan","year":"2024","unstructured":"Fan Y, Zhang W, Iqbal Z, et al. Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy. Lipids Health Dis. 2024;23(1):318. https:\/\/doi.org\/10.1186\/s12944-024-02301-y.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"7790_CR68","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.stem.2024.10.007","volume":"31","author":"C Liu","year":"2024","unstructured":"Liu C, Shen M, Liu Y, et al. CRISPRi\/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. Cell Stem Cell. 2024;31(12):1760\u201376. https:\/\/doi.org\/10.1016\/j.stem.2024.10.007.","journal-title":"Cell Stem Cell"},{"key":"7790_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17164","author":"W Xia","year":"2024","unstructured":"Xia W, Chen H, Yang H, et al. Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin-related cardiotoxicity. FEBS J. 2024. https:\/\/doi.org\/10.1111\/febs.17164.","journal-title":"FEBS J"},{"issue":"2","key":"7790_CR70","doi-asserted-by":"publisher","first-page":"e074541","DOI":"10.1136\/bmjopen-2023-074541","volume":"14","author":"W Ou","year":"2024","unstructured":"Ou W, Jiang T, Zhang N, et al. Role of HDL cholesterol in anthracycline-induced subclinical cardiotoxicity: a prospective observational study in patients with diffuse large B-cell lymphoma treated with R-CHOP. BMJ Open. 2024;14(2):e074541. https:\/\/doi.org\/10.1136\/bmjopen-2023-074541.","journal-title":"BMJ Open"},{"issue":"1","key":"7790_CR71","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1002\/cai2.151","volume":"4","author":"P Li","year":"2025","unstructured":"Li P, Liu D, Gao P, et al. Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin. Cancer Innov. 2025;4(1):e151. https:\/\/doi.org\/10.1002\/cai2.151.","journal-title":"Cancer Innov"},{"issue":"6","key":"7790_CR72","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s10557-023-07464-x","volume":"38","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Peng J, Hu Y, et al. CTRP5 attenuates doxorubicin-induced cardiotoxicity via inhibiting TLR4\/NLRP3 signaling. Cardiovasc Drugs Ther. 2024;38(6):1235\u201344. https:\/\/doi.org\/10.1007\/s10557-023-07464-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7790_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-025-07672-7","volume":"15","author":"Y Hu","year":"2025","unstructured":"Hu Y, Wang S, Zhang C, et al. Downregulated TRIM35 alleviates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via inhibiting TLR4\/NF-\u03baB pathway. Cardiovasc Drugs Ther. 2025;15:1. https:\/\/doi.org\/10.1007\/s10557-025-07672-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7790_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113677","volume":"144","author":"E Qaed","year":"2025","unstructured":"Qaed E, Liu W, Al-mashriqi HS, et al. Protective effects of phosphocreatine against doxorubicin-induced cardiotoxicity through mitochondrial function enhancement and apoptosis suppression via AMPK\/PGC-1\u03b1 signaling pathway. Int Immunopharmacol. 2025;144:113677. https:\/\/doi.org\/10.1016\/j.intimp.2024.113677.","journal-title":"Int Immunopharmacol"},{"key":"7790_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.135904","volume":"281","author":"S Nalinbenjapun","year":"2024","unstructured":"Nalinbenjapun S, Sripetthong S, Basit A, et al. Fabrication of curcumin-loaded nano-micelles based on quercetin-quarternary ammonium-chitosan (Qu-QCS) conjugate and evaluation of synergistic effect with doxorubicin against breast cancer. Int J Biol Macromol. 2024;281:135904. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135904.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"7790_CR76","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s12282-024-01623-0","volume":"31","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Fujiki S, Okura Y, et al. Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese community. Breast Cancer. 2024;31(6):1080\u201391. https:\/\/doi.org\/10.1007\/s12282-024-01623-0.","journal-title":"Breast Cancer"},{"key":"7790_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.912329","volume":"9","author":"W Huang","year":"2022","unstructured":"Huang W, Xu R, Zhou B, et al. Clinical manifestations, monitoring, and prognosis: a review of cardiotoxicity after antitumor strategy. Front Cardiovasc Med. 2022;9:912329. https:\/\/doi.org\/10.3389\/fcvm.2022.912329.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"7790_CR78","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18087\/cardio.2024.9.n2743","volume":"64","author":"IY Sokolova","year":"2024","unstructured":"Sokolova IY, Murtuzaliev SM, Kardovskaya SA, et al. Assessment of specific biomarkers\u2019 profile and structural, functional parameters of the left ventricle in patients with lymphomas undergoing antitumor therapy. Kardiologiia. 2024;64(9):28\u201338. https:\/\/doi.org\/10.18087\/cardio.2024.9.n2743.","journal-title":"Kardiologiia"},{"issue":"1","key":"7790_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87209-8","volume":"11","author":"HV Lakhani","year":"2021","unstructured":"Lakhani HV, Pillai SS, Zehra M, et al. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Sci Rep. 2021;11(1):7954. https:\/\/doi.org\/10.1038\/s41598-021-87209-8.","journal-title":"Sci Rep"},{"issue":"1","key":"7790_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05088-9","volume":"22","author":"C Thonusin","year":"2024","unstructured":"Thonusin C, Osataphan N, Leemasawat K, et al. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients. J Transl Med. 2024;22(1):398. https:\/\/doi.org\/10.1186\/s12967-024-05088-9.","journal-title":"J Transl Med"},{"issue":"8","key":"7790_CR81","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00259-024-06673-2","volume":"51","author":"Z Wei","year":"2024","unstructured":"Wei Z, Xu H, Chen B, et al. Early detection of anthracycline-induced cardiotoxicity using [68 Ga] Ga-FAPI-04 imaging. Eur J Nucl Med Mol Imaging. 2024;51(8):2204\u201315. https:\/\/doi.org\/10.1007\/s00259-024-06673-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7790_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101033","volume":"26","author":"K Nakata","year":"2024","unstructured":"Nakata K, Kucukseymen S, Cai X, et al. Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity. J Cardiovasc Magn Reson. 2024;26(1):101033. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101033.","journal-title":"J Cardiovasc Magn Reson"},{"key":"7790_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103755","volume":"76","author":"R Rosenfeld","year":"2024","unstructured":"Rosenfeld R, Riondino S, Cerocchi M, et al. Extracellular volume measured by whole body CT scans predicts chronic cardiotoxicity in breast cancer patients treated with neoadjuvant therapies based on anthracyclines: a retrospective study. Breast. 2024;76:103755. https:\/\/doi.org\/10.1016\/j.breast.2024.103755.","journal-title":"Breast"},{"issue":"3","key":"7790_CR84","doi-asserted-by":"publisher","first-page":"zqae008","DOI":"10.1093\/function\/zqae008","volume":"5","author":"S Nath","year":"2024","unstructured":"Nath S, Balling R. The warburg effect reinterpreted 100 yr on: a first-principles stoichiometric analysis and interpretation from the perspective of ATP metabolism in cancer cells. Function. 2024;5(3):zqae008. https:\/\/doi.org\/10.1093\/function\/zqae008.","journal-title":"Function"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07790-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:47Z","timestamp":1778649707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7790"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07790-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"1 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}